VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

02 1 2024 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

17 11 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces November 2023 Investor Conference Participation

08 11 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

02 11 2023 03:04:23 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

19 10 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

06 10 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

03 10 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

11 9 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

06 9 2023 02:00:00 提供 Nasdaq GlobeNewswire

Christina Ackermann Joins Verona Pharma as Non-Executive Director

31 8 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

03 8 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

26 7 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

20 7 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

28 6 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

27 6 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

24 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

02 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

25 4 2023 02:00:00 提供 Nasdaq GlobeNewswire

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

10 4 2023 02:00:00 提供 Nasdaq GlobeNewswire